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Abstract
Background: Advanced maternal age, family history of diabetes, pre-gestational obesity, increased level of HbA1c,
history of gestational diabetes mellitus (GDM), and poor pregnancy consequences are considered risk factors for
antenatal insulin requirement in women with GDM. However, the role of assisted reproductive technology (ART) in
increasing the risk of insulin therapy in pregnancies complicated with GDM remained elusive. The current study
aimed to determine the role of ART in predicting insulin therapy in GDM women and investigate the clinical and
biochemical factors predicting the need for insulin therapy in pregnancies complicated with GDM.
Methods: In this prospective cohort study, 236 Iranian women with GDM were diagnosed by one-step oral glucose
tolerance test (OGTT) between October 2014 and June 2017. They were mainly assigned to two groups; the first
group (n = 100) was designated as ART which was further subdivided into two subgroups as follows: 60 participants
who received medical nutrition therapy (MNT) and 40 participants who received MNT plus insulin therapy (MNT-IT).
The second group (n = 136) was labeled as the spontaneous conception (SC), consisting of 102 participants
receiving MNT and 34 participants receiving MNT in combination with IT (MNT-IT). The demographic, clinical, and
biochemical data were compared between groups. Multivariate logistic regression was performed to estimate
prognostic factors for insulin therapy.
Results: A higher rate of insulin therapy was observed in the ART group as compared with the SC group (40% vs.
25%; P < 0.001). Multivariate logistic regression demonstrated that maternal age ≥ 35 years [OR: 2.91, 95% CI: (1.28–
6.62)], high serum FBS [1.10: (1.04–1.16)], HbA1c [1.91 (1.09–3.34)], and ART treatment [2.94: (1.24–6.96)] were
independent risk factors for insulin therapy in GDM women.
Conclusions: Apart from risk factors mentioned earlier, ART may be a possible prognostic factor for insulin therapy
in pregnancies complicated with GDM.
Keywords: Gestational diabetes mellitus, Insulin, Prognostic factors, Assisted reproductive technology, Pregnancy
© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
* Correspondence: akouhkan@royaninstitute.org; azamkouhkan@yahoo.com;
Khamseh.m@iums.ac.ir; khamseh.m@iums.ac.ir
1Reproductive Epidemiology Research Center, Royan Institute for
Reproductive Biomedicine, ACECR, Tehran, Iran
3Endocrine Research Center, Institute of Endocrinology and Metabolism, Iran
University of Medical Sciences (IUMS), Firouzeh St., South Vali- Asr Ave., Vali-
Asr Sq, Tehran, Iran
Full list of author information is available at the end of the article
Kouhkan et al. Reproductive Biology and Endocrinology           (2019) 17:83 
https://doi.org/10.1186/s12958-019-0525-4
Introduction
Assisted reproductive technology (ART) is increasingly
being practiced worldwide. Besides, gestational diabetes
mellitus (GDM) has become more prevalent in obese
women conceived via ART treatments [1]. Several lines
of evidence demonstrate that both ART and GDM are
associated with adverse pregnancy outcomes as com-
pared to those with natural conception [2, 3]. Current
reports indicate that a history of infertility can increase
the risk of GDM independent of the known risk factors
[4, 5]. Furthermore, a higher prevalence of GDM in
women who became pregnant by ART was previously
reported [5]. Therefore, GDM, as a marked co-
morbidity, should be early diagnosed and managed
appropriately.
As the pregnancy proceeds, insulin resistance is grad-
ually increased, especially in the third trimester of the
gestational period [6]. Obesity and insulin-resistance re-
duce the functionality of β-cells and induce inflamma-
tion thought to play key roles in the development of
GDM [7]. In this circumstance, early management of
GDM which is of immense importance includes medical
nutrition therapy (MNT), self-blood glucose monitoring,
physical activity, and regular consumption of medica-
tions to control hyperglycemia [8]. Approximately 20–
60% of GDM women need pharmacological treatments
to control their blood sugar [9]. Insulin is considered a
safe and effective medication for women with GDM who
failed to respond to medical nutrition therapy [8]. Ad-
equate and accurate control of blood glucose can attenu-
ate adverse maternal and perinatal outcomes [10].
However, factors predicting antenatal insulin require-
ment in women with GDM have not been fully under-
stood. Some risk factors, such as advanced maternal age,
family history of diabetes, pre-gestational obesity, high
oral glucose tolerance test (OGTT) values, history of
GDM or poor pregnancy consequences, and polycystic
ovary syndrome (PCOS) have been previously addressed
in the literature [11, 12].
However, the role of ART in increasing the risk of in-
sulin therapy in women with GDM remained opaque.
Hence, this study was designed to explore the role of
ART in predicting insulin therapy in women with GDM.
Moreover, we examined the predictive potential of clin-
ical and biochemical parameters for insulin therapy in
the management of women with GDM.
Participants and methods
The present research was a prospective cohort study that
included 236 Iranian singleton pregnant women (aged
20–40 years) with GDM who recruited between October
2014 and June 2017. All participants consisted of ART
and spontaneous conception (SC) groups enrolled by
simple sampling following GDM diagnosis. Medical
records of Iranian GDM pregnant women were regis-
tered. The ART group included singleton pregnancies
conceived following in-vitro fertilization /intra-cytoplas-
mic sperm injection (IVF/ICSI) or ICSI cycles that re-
ferred to the Department of Endocrinology and Female
Infertility of the Royan Institute, Tehran, Iran. The
protocol of infertility treatment in our institute was in
agreement with the standard international guidelines.
The pregnant women with no history of infertility
and/or infertility treatments were designated the SC
group who referred to the Obstetrics and Gynecology
Clinic of Arash Women’s Hospital which affiliated with
Tehran University of Medical Science. Written informed
consent was taken from all participants before the
enrollment.
The diagnosis of GDM was made by a one-step OGTT
at 24 and 28 weeks of gestation. The American Diabetes
Association/International Association of the Diabetes
and Pregnancy Study Groups (ADA/IAPDSG) criteria
were considered to diagnose GDM [8]. The exclusion
criteria were: (1) any systemic disorders, (2) pregravid
diabetes or glucose intolerance, (3) previous insulin
treatment, (4) consuming oral glucose-lowering drugs
(metformin and glibenclamide), (5) vanishing embryos
or selective fetal reduction, (6) history of polycystic ovar-
ian syndrome (PCOS), and (7) twin pregnancies. The In-
stitutional Review Board and Ethics committee of the
Iran University of Medical Sciences and Royan institute
approved the present study.
Clinical and demographic data were obtained from
medical records and face-to-face interviews. In these two
centers, the weight (without shoes with the least clothes)
of women was measured by Seca scale, and the height
was determined by a stadiometer. Pre-pregnancy body
mass index (BMI) [pre-pregnancy weight (kg)/height (m)
2] was calculated according to the standard formula. Sys-
tolic and diastolic blood pressure was assessed by trained
nurses with a mercury sphygmomanometer at 24–28
weeks of gestation. The mean systolic and diastolic
blood pressure was recorded in duplicate. Venous blood
samples were collected at 24 and 28 weeks of gestation
for the determination of fasting blood sugar (FBS),
hemoglobin A1c (HbA1c), insulin, a high-sensitivity C-
reactive protein (hs-CRP), and interleukin-17 (IL-17), as
well as the lipid profile, i.e., cholesterol, triglycerides
(TG), high density lipoprotein (HDL), low density lipo-
protein (LDL), and very-low-density lipoproteins
(VLDL), after 8–12 h’ fast. The Homeostasis Model As-
sessment of insulin resistance (HOMA-IR) index was
also calculated.
All GDM women referred to an endocrinologist and a
dietician for blood sugar management, Medical nutrition
therapy (MNT), and nutrition plan, and consultation.
Medical nutrition therapy (MNT) was defined as the
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management of GDM with optimal diet (energy content,
macronutrient distribution, its quality and amount) to
achieve sufficient mother’s weight gain and fetal growth,
as well as maintaining near-normoglycemia and avoiding
the development of ketone bodies and hypoglycemia.
The participants were asked to take three main meals
with three snacks per day and perform self-monitoring
of blood glucose (SMBG). After 2 weeks of MNT, all
participants were visited again by an endocrinologist.
Fasting and postprandial sugar (2 h after breakfast,
lunch, and dinner) were evaluated. If FBS was lower than
95mg/dl, the 1-h postprandial blood sugar level was <
140 mg/dl, and 2-h postprandial blood sugar level was <
120 mg/dl, MNT alone continued. Insulin therapy (IT)
was initiated by an endocrinologist when medical nutri-
tion therapy failed, and fasting/postprandial blood glu-
cose levels were above the target at any time during
pregnancy. Subcutaneous injections of the rapid-acting
and/or long-acting insulin were prescribed according to
the blood glucose patterns.
The ovarian stimulation protocols and follow-up
process after standard IVF/ICSI procedures were de-
scribed previously in details [13]. ART drugs, the proto-
col of controlled ovarian stimulation (COS) using
standard GnRH agonists or antagonists, as well as the
modes of ART (fresh or frozen embryo transfer cycles)
were obtained from the medical registry of infertile
women. Ovarian hyper-stimulation syndrome (OHSS) is
characterized by the increased level of serum estradiol
(> 4000 pg/ml) along with a large number (> 20 per
ovary) of follicles on the day of human chorionic go-
nadotropin (hCG) administration. Infertile women who
were at higher risk of developing OHSS, frozen embryo
transfer was performed by the vitrification method.
Data related to the ART procedures, including menar-
che age, infertility duration, irregular menstrual cycle, in-
fertility type (secondary vs. primary), history of ovarian
hyperstimulation syndrome (OHSS) risk, ovarian stimu-
lation protocol (standard GnRH agonists vs. GnRH an-
tagonists), and the method of ART [fresh embryo
transfer (fresh ET) vs. frozen ET)] were obtained from
women receiving infertility treatments.
Other variables that were considered in the final ana-
lysis were as follows; maternal age, BMI, history of hav-
ing a first-degree relative with diabetes, prior history of
spontaneous abortion, and macrosomic baby, history of
GDM, increased OGTT values (GTT-FBS and GTT-2
h), increased levels of HbA1c, mode of conception, and
GDM treatment modalities (MNT /MNT- IT).
Statistical analysis
In the current study, continuous variables were pre-
sented as the means and standard error of the mean
(mean ± SEM) and categorical variables were expressed
as the percentage. The chi-square test and independent
T-tests were applied to compare variables between the
two groups as indicated. The univariate logistic regres-
sion analysis was carried out to compare the characteris-
tics of participants receiving either MNT-IT or MNT
and select the variables for entering in the multivariate
model, as well as determining significant predictive fac-
tors for insulin requirement in the study population. All
statistical analyses were two-sided, and the p-value of <
0.05 was considered statistically significant. The analysis
of the obtained values was performed by the Stata soft-
ware version 12.
Based on previous studies [14–16], a sample size of
236 GDM women would be necessary to obtain a power
of 80% with a significance level α = 5% to detect a rela-
tionship between the type of conception and the need
for insulin therapy.
Results
In this study, 100 GDM women conceived via ART and
136 GDM women conceived via spontaneous conception
were included. All participants were stratified based on
the treatment modalities receiving during pregnancy
[i.e., medical nutrition therapy (MNT) or medical nutri-
tion therapy plus insulin therapy (MNT-IT)]. In the
ART group, 60 subjects were in the MNT sub-group
and 40 subjects in the MNT-IT subgroup. In the SC
group, 102 subjects were assigned to the MNT sub-
group and 34 subjects in the MNT-IT subgroup. Figure 1
shows a flow diagram of the categorization of partici-
pants. The results showed a higher rate of participants
in the ART group who required insulin treatment com-
pared with individuals in the SC group [40 (40%) vs. 34
(25%), respectively; P < 0.001].
The clinical and biochemical characteristics of women
in both groups are summarized in Table 1. Based on our
results, there was no significant difference between SC
and ART groups in terms of the mean maternal age, sys-
tolic and diastolic blood pressure, and the number of in-
dividuals with a family history of diabetes, prior history
of spontaneous abortion, and macrocosmic baby. How-
ever, there was a significant difference between the two
groups concerning the parity, pre-pregnancy BMI, and
history of GDM. Besides, most biochemical characteris-
tics were not significantly different except for serum FBS
and hs-CRP levels.
The clinical characteristics between the two groups
were stratified based on treatment modalities that are
displayed in Table 2. Higher rates of maternal age ≥ 35
years, multiparty, pre-pregnancy BMI ≥25 (kg/m2) and
prior history of GDM were observed in the MNT-IT
subgroup of the SC group; however, such increments
were not statistically significant when compared with the
MNT subgroup of the ART group. In the ART group,
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the MNT-IT subgroup had a higher rate of family his-
tory of diabetes compared with the MNT subgroup.
The results of the univariate logistic regression analysis
are presented in Table 2 and show the risk factors of in-
sulin therapy in the study population. The parameters
associated with insulin requirement in total population
were as follows; maternal age ≥ 35 years, family history of
diabetes mellitus (DM), pre-pregnancy BMI, previous
history of spontaneous abortion, and prior history of
GDM. However, there were no significant differences
between MNT and MNT-IT subgroups of the ART
group in terms of ART parameters (P > 0.05) (Table 3).
None of the infertility parameters was associated with
insulin therapy in this group.
Fig. 1 The Flow chart of the study population
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The biochemical values of the SC and ART participants
were stratified according to the treatment modalities that
are depicted in Table 4. The mean concentrations of FBS
and HbA1c were significantly higher in the MNT-IT sub-
group of the SC group compared with the MNT subgroup.
Similar findings were observed in the MNT-IT subgroup of
the ART group when compared with MNT subgroup. The
higher levels of one- and two-hour glucose after OGTT
were observed in the MNT-IT subgroup of the SC group in
comparison with the MNT subgroup. However, such values
were not significantly different between the MNT and
MNT-IT subgroups of the ART population (P > 0.05). The
mean concentrations of TG and VLDL were significantly
higher in the MNT-IT subgroup of the ART group as com-
pared with the MNT subgroup. The mean levels of the in-
flammatory markers were higher in the MNT-IT subgroup
compared with the MNT subgroup of the ART group. In
the total population, higher levels of GTT-FBS, GTT-1 h,
GTT-2 h, FBS, and HbA1c, as well as hs-CRP, were
observed in the MNT-IT subgroup compared with the
MNT subgroup of the ART group.
The analysis of multivariate logistic regression was
conducted to determine the predictive factors linked
with insulin therapy (Table 5). Factors identified as prog-
nostic factors of insulin therapy were the age equal to or
above 35 years old [OR: 2.91, 95% CI: (1.28–6.62)], in-
creased levels of GTT- FBS [1.10: (1.04–1.16)], HbA1c
[1.91 (1.09–3.34)], as well as ART treatment. The mode
of conception (ART treatment) was identified as the in-
dependent prognostic factor for insulin requirement in
GDM women after the adjustment (or controlling) of
other confounding factors or covariates [OR: 2.94, 95%
CI: (1.24–6.96)].
Discussion
The present study found that maternal age ≥ 35 years
old, elevated fasting glucose, and increased levels of
HbA1c were the independent risk factor for insulin
Table 1 Comparison of clinical and biochemical characteristics between spontaneous conception and ART participants
Variables SC (n = 136) ART (n = 100) †P-value
Clinical
Maternal age (Years, Mean ± SE) 31.57 ± 0.46 32.36 ± 0.52 0.261
Parity (n = 0), n (%) 56 (41.2) 88 (87.1) 0.001*
Family history of DM, (Yes, n %) 52 (38.2) 42 (41.6) 0.602
Systolic blood pressure (Mean ± SE) 107.07 ± 0.87 106.68 ± 0.99 0.769
Diastolic blood pressure (Mean ± SE) 68.59 ± 0.72 66.83 ± 0.76 0.098
Pre-pregnancy BMI (Mean ± SE) 25.89 ± 0.42 27.32 ± 0.40 0.018*
Prior history of spontaneous abortion, (Yes), n (%) 36 (29.1) 32 (31.7) 0.670
Prior history of GDM, (Yes), n (%) 18 (13.2) 1 (0.9) 0.001*
Prior history of macrosomia, (Yes), n (%) 6 (4.4) 1 (0.9) 0.124
Biochemical
GTT-FBS (mg/dl)(Mean ± SE) 93.38 ± 0.87 93.13 ± 0.96 0.851
GTT-1 h(mg/dl)(Mean ± SE) 162.93 ± 4.11 158.22 ± 4.72 0.455
GTT-2 h(mg/dl)(Mean ± SE) 134.29 ± 3.71 133.26 ± 3.67 0.847
FBS (mg/dl)(Mean ± SE) 84.21 ± 1.05 88.23 ± 0.95 0.006*
HbA1c (%) (Mean ± SE) 4.98 ± 0.10 5.07 ± 0.63 0.297
TG (mg/dl)(Mean ± SE) 200.61 ± 6.13 193.42 ± 5.62 0.254
Cholesterol (mg/dl)(Mean ± SE) 219.91 ± 3.52 210.86 ± 4.43 0.107
HDL (mg/dl)(Mean ± SE) 64.17 ± 1.34 63.49 ± 1.26 0.715
LDL (mg/dl)(Mean ± SE) 116.13 ± 3.01 110.31 ± 4.01 0.238
VLDL (mg/dl)(Mean ± SE) 40.05 ± 1.24 37.19 ± 1.28 0.115
Hs-CRP (Mean ± SE) 4.69 ± 0.40 7.21 ± 0.83 0.005*
IL-17 (Mean ± SE) 1.19 ± 0.26 2.66 ± 0.95 0.161
Insulin (Mean ± SD) 13.57 ± 140 13.98 ± 0.96 0.821
HOMA-IR 2.90 ± 0.34 3.09 ± 0.23 0.672
SC spontaneous conception, ART Assisted reproductive technology, IL-17 Interleukin- 17, Hs-CRP High-sensitivity C - reactive protein, The Homeostasis Model
Assessment of insulin resistance (HOMA-IR) index = [Glucose] * [Insulin] / 405 (Glucose in mg/dl)
*P < 0.05 was considered statistically significant
† T-test compared the mean difference between the SC group and ART group
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Table 2 Comparison of clinical parameters between parturients with spontaneous and ART conception stratified based on
treatment modalities
Variables SC (n = 136) ART (n = 100) OR3 (CI 5%)
c
P-
valueMNT (n =
102)
MNI-IT (n =
34)
OR1 (CI 95%)
a
P-
value
MNT (n =
60)
MNT-IT
(n = 40)
OR2 (CI
95%) b
P-
value
Maternal age (Years, Mean ±
SE)
30.64 ±
0.53
34.38 ±
0.73
1.17 (1.07–
1.28)
0.001* 32.05 ±
0.77
32.65 ± 0.62 1.02 (0.95–
1.10)
0.576 1.94 (1.10–
3.41)
0.023*
Maternal age≥ 35 years,n (%) 26 (25.5) 16 (47.0) 2.6 (1.16–
5.82)
0.018* 19 (31.7) 15 (37.5) 1.29 (0.55–
2.99)
0.546 1.87 (1.05–
3.33)
0.032*
Parity (n = 0), n (%) 46 (45.1) 10 (29.4) 11.97 (0.86–
4.54)
0.108 50 (83.3) 37 (92.5) 0.41 (0.10–
1.58)
0.182 0.84 (0.47–
1.47)
0.535
Family history of DM (Yes, n
%)
35 (34.3) 17 (50.0) 1.91 (0.87–
4.20)
0.103 20 (33.3) 22 (55.0) 2.44 (1.07–
5.56)
0.033* 2.17(1.24–
3.79)
0.007*
Systolic blood pressure
(Mean ± SE)
106.37 ±
1.01
109.11 ±
0.72
1.03 (0.99–
1.07)
0.176 107.25 ±
1.17
106.0 ± 1.82 0.99 (0.95–
1.03)
0.542 1.01 (0.98–
1.03)
0.424
Diastolic blood pressure
(Mean ± SE)
68.22 ±
0.83
69.71 ±
1.42
1.02 (0.97–
1.07)
0.367 66.83 ±
0.98
67.0 ± 1.25 1.00 (0.96–
1.06)
0.915 1.0 (0.97–
1.04)
0.574
Pre-pregnancy BMI (Mean ±
SE)
25.44 ±
0.49
27.31 ±
0.81
1.08 (1.00–
1.17)
0.059 27.22 ±
0.46
27.52 ± 0.76 1.01 (0.95–
1.12)
0.726 1.94 (1.09–
3.45)
0.022*
Pre-pregnancy BMI ≥25 (kg/
m2), n (%)
49(49.1) 23 (71.9) 2.65 (1.12–
6.31)
0.024* 43 (71.7) 29 (72.5) 1.04 (0.43–
2.55)
0.928 1.92 (1.05–
3.51)
0.034*
History of spontaneous
abortion, n (%)
26 (26.0) 13 (38.2) 1.76 (0.77–
4.02)
0.175 16 (26.7) 16 (40) 1.83 (0.78–
4.30)
0.161 1.90 (1.12–
3.23)
0.018*
History of GDM, (Yes, n %) 8 (7.8) 10 (29.4) 4.90 (1.74–
13.74)
0.001* 1 (1.7) 0 (0) – 1 2.66 (1.03–
6.84)
0.043*
History of macrosomia, (Yes, n
%)
4 (3.9) 2 (5.8) 1.53 (0.27–
8.76)
0.630 1 (1.7) 0 (0) 0.87 (0.16–
4.60)
0.872 0.66 (0.13–
3.35)
0.619
CI Confidence Interval, GDM gestational diabetes mellitus, SC Spontaneous Conception, ART Assisted Reproductive Technology, MNT Medical Nutrition Therapy,
MNT-IT Medical Nutrition Therapy plus Insulin Therapy
*P < 0.05 was considered statistically significant
a OR1; Fitting GDM treatment modality as the outcome of the univariate regression models. The reference group was the MNT subgroup compared to the MNT-IT
in SC group
b OR2; Fitting GDM treatment modality as the outcome of the univariate regression models; The reference group was the MNT subgroup compared to the MNT-IT
in ART group
c OR3; Fitting GDM treatment modality as the outcome of the univariate regression models; The reference group was the MNT subgroup compared to the MNT-IT
in the total population
Table 3 Infertility parameters of ART-conceived parturients stratified based on the treatment modalities
Variables MNT
(n = 60)
MNT-IT (n = 40) P-value
Menarche age, years (Mean ± SE) 13.1 ± 0.2 13.6 ± 0.3 0.532
Infertility duration, years, (Mean ± SE) 6.2 ± 0.5 7.5 ± 0.8 0.117
Irregular menstrual cycle, n (%) 7 (11.7) 3 (7.5) 0.496
Infertility type (Secondary), n (%) 25 (41.7) 17 (42.5) 0.934
Prior OHSS risk, n (%) 23 (38.3) 17 (42.5) 0.677
COH protocol
Standard long GnRH agonist, n (%) 44 (77.2) 35 (87.5) 0.199
ART mode
Fresh ET, n (%) 28 (51.9) 23 (57.5) 0.587
MNT Medical Nutrition Therapy, MNT-IT Medical Nutrition Therapy plus Insulin Therapy, Fresh ET Fresh embryo transfer
*P < 0.05 was considered statistically significant
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therapy. Furthermore, infertility treatment using assisted
reproductive technology may be a possible predictive
factor for insulin therapy in women with GDM.
The prevalence of GDM in Iran ranges from 1.3 to
18.8% in different geographical regions [16]. A recent
systematic review and meta-analysis revealed that GDM
treatment reduces the risk of delivering infants with
macrosomia (i.e., being large-for-gestational-age birth),
shoulder dystocia, and gestational hypertension. Of note,
GDM treatment causes no significant increase in the risk
of small-for-gestational-age birth [17]. Regarding the
global increment in gestational diabetes, determination
of high-risk populations requiring insulin therapy is cru-
cial. Lifestyle modification is the first-line therapy for the
management of women with GDM. However, some
GDM women require insulin therapy as they the change
in their lifestyle would not be sufficient alone.
Assisted conception, a standard treatment for infertility,
is growing worldwide. Several unknown and concomitant
factors in women conceived via ART make them prone to
develop complications during their pregnancy, such as
gestational diabetes which influences the clinical practice.
Recently, Chen et al. [18] observed that peripheral insulin
sensitivity is reduced in IVF-conceived women. They also
reported the alternation of glucose metabolism (impaired
glucose tolerance) in IVF-conceived mice. On the basis of
the current data, insulin requirement was significantly
higher in the ART group compared with the SC group
(40% vs. 25%). Previously, antenatal insulin requirement
was reported in 10.8–52.8% of GDM women after spon-
taneous conception [5, 19].
Several studies investigated clinical and biochemical
parameters predicting the need for insulin therapy in
GDM women who spontaneously conceived [11, 12, 19–
22]. Moreover, some studies suggested similar prognos-
tic factors, including advanced age [11, 23], elevated fast-
ing glucose [14, 15, 20, 23], elevated two-hour glucose
Table 4 Comparison of biochemical parameters between parturients with spontaneous and ART conception stratified based on
treatment modalities
Variables SC (n = 136) ART (n = 100) P-
valuecMNT (n = 102) MNI-IT (n = 34) P-value a MNT (n = 60) MNT-IT (n = 40) P-valueb
GTT-FBS (mg/dl)(Mean ± SE) 91.69 ± 0.95 98.18 ± 1.66 0.001* 90.67 ± 1.20 96.92 ± 1.42 0.001* 0.002*
GTT-1 h (mg/dl)(Mean ± SE) 156.10 ± 4.46 183.90 ± 8.66 0.003* 159.14 ± 5.98 156.82 ± 7.98 0.813 0.014*
GTT-2 h (mg/dl)(Mean ± SE) 129.38 ± 4.19 147.40 ± 7.34 0.003* 131.0 ± 4.50 136.58 ± 6.39 0.464 0.046*
FBS (mg/dl) (Mean ± SE) 82.89 ± 1.21 88.03 ± 1.77 0.032* 85.98 ± 0.99 91.44 ± 1.77 0.004* 0.030*
HbA1c (%) (Mean ± SE) 4.92 ± 0.07 5.40 ± 0.12 0.005* 4.85 ± 0.10 5.16 ± 0.08 0.022* 0.004*
TG (mg/dl) (Mean ± SE) 201.12 ± 6.83 199.11 ± 13.71 0.887 175.31 ± 8.16 204.97 ± 9.69 0.026* 0.065
Cholesterol (mg/dl) (Mean ± SE) 221.33 ± 4.20 215.71 ± 6.36 0.491 202.09 ± 4.58 223.13 ± 7.97 0.019* 0.066
HDL (mg/dl) (Mean ± SE) 64.61 ± 1.56 62.85 ± 2.60 0.573 65.20 ± 1.74 60.81 ± 1.65 0.097 0.083
LDL (mg/dl) (Mean ± SE) 117.30 ± 3.89 112.52 ± 6.54 0.496 101.83 ± 4.35 121.42 ± 6.93 0.014* 0.105
VLDL (mg/dl) (Mean ± SE) 40.19 ± 1.36 39.59 ± 2.84 0.836 35.06 ± 1.66 40.90 ± 1.92 0.029* 0.089
hs-CRP (mg/l) (Mean ± SE) 4.60 ± 0.41 5.06 ± 1.16 0.651 6.45 ± 0.75 8.69 ± 1.95 0.049* 0.010*
IL-17(pg/mL) (Mean ± SE) 1.21 ± 0.27 0.70 ± 0.60 0.660 0.91 ± 0.19 5.52 ± 2.35 0.017b 0.061
Insulin (mU/L) (Mean ± SE) 12.90 ± 1.64 15.87 ± 2.58 0.375 13.26 ± 1.36 14.92 ± 1.29 0.411 0.191
HOMA-IR 2.76 ± 0.42 3.39 ± 0.49 0.443 2.86 ± 0.33 3.40 ± 0.31 0.255 0.202
GDM Gestational Diabetes Mellitus, SC Spontaneous Conception, ART Assisted Reproductive Technology, MNT Medical Nutrition Therapy, MNT-IT Medical Nutrition
Therapy plus Insulin Therapy
The Homeostasis Model Assessment of insulin resistance (HOMA-IR) index = [Glucose] * [Insulin] / 405 (Glucose in mg/dl)
*P < 0.05 was considered significant
a T-test compared the mean difference between MNT and MNT-IT subgroups in the SC group
bT-test compared the mean difference between MNT and MNT-IT subgroups in the ART group
c T-test compared the mean difference between MNT and MNT-IT subgroups in total population
Table 5 The multivariate logistic regression analysis for the risk
factors associated with insulin therapy
Model OR (CI 95%)a
Age≥ 35 yr. (Yes/No) 2.91 (1.28–6.62)†
Prior history of GDM (Yes/No) 3.22 (0.83–12.51)
GTT-FBS (mg/dl) 1.10 (1.04–1.16) †
GTT-2 h (mg/dl) 1.01 (0.99–1.02)
Family history of DM (Yes/No) 1.06 (0.45–2.45)
HbA1c (%) 1.91 (1.09–3.34)†
BMI≥ 25 (kg/m2) 2.12 (0.84–5.37)
Mode of conception (ART/SC) 2.94 (1.24–6.96)†
Data are presented as odds ratios (95% confidence interval)
MNT-IT was compared to MNT: Reference group was MNT
†P < 0.05 was considered statistically significant
a OR; Fitting GDM treatment modality as the outcome of the multivariate
regression models;
Kouhkan et al. Reproductive Biology and Endocrinology           (2019) 17:83 Page 7 of 10
[14], prior history of GDM [15], and HbA1c [12, 15, 20,
21] for insulin treatment. Conversely, some reports dem-
onstrated that the elevated pre-pregnancy BMI [12, 14,
15, 23], family history of diabetes [12, 20], and elevated
1-h blood glucose after GTT [14, 15, 20] were poten-
tially independent prognostic factors. More recently,
Barens et al. indicated a prediction model for insulin
therapy in GDM women. According to this model, seven
significant independent prognostic factors have been in-
troduced, namely maternal age > 30 years, pre-gravid
obesity (BMI ≥30 kg/m2), prior history of GDM, FBS ≥
5.3 mmol/l, HbA1c ≥ 5.5% at the initial diagnosis of
GDM, early diagnosis of GDM (< 24 weeks of gestation),
and family history of diabetes. They concluded that
85.7–93.1% of women had six to seven prognostic fac-
tors mentioned above, but 9.3–14% of women had no or
one prognostic factor [11].
The present results revealed that age ≥ 35 years, elevated
GTT-FBS, and HbA1c were the independent risk factors
for insulin therapy. Interestingly, the current study found
a new prognostic factor for insulin therapy in pregnant
women with GDM. The risk of insulin requirement was
2.94 folds higher in the ART group compared with the SC
group. However, little is known about the association be-
tween ART and the risk of GDM. Previous evidence
showed that infertile women and ART population were
susceptible to develop GDM [4, 13]; yet, the mechanism
underlying ART-induced insulin resistance and insulin re-
quirement is partially understood. We assessed the impact
of some aspects of ART properties on antenatal insulin re-
quirement and observed no significant difference between
MNT and MNT-IT subgroups of the ART group with re-
spect to the ART parameters. Several hypotheses may be
proposed in this regard.
First, the experimental study showed ART-induced
endothelial dysfunction and arterial hypertension, glu-
cose intolerance, and insulin resistance [24]. Second,
some ART characteristics may be in charge of insulin re-
sistance and the need for insulin therapy, such as PCOS
[25], the number of embryo transfer, and administration
of GnRH agonist during the COS cycle in ART. Third,
infertile women usually receive exogenous progesterone
during the luteal phase and at the first trimester of preg-
nancy, which may be associated with gestational diabetes
and insulin resistance. Similar mechanisms might be
proposed for insulin requirement in patients who
undergo ART treatment. Nunes et al. found that proges-
terone- particularly at pharmacological doses- increased
the generation of reactive oxygen species (ROS), and it
could be toxic to pancreatic β-cells as a result of oxida-
tive stress [26].
Moreover, Wada et al. [27] showed the molecular mech-
anisms of progesterone involved in the pathogenesis of in-
sulin resistance during pregnancy. They indicated that
progesterone could induce insulin resistance by the inhib-
ition of GLUT-4 translocation, a decrease in the expres-
sion of the insulin receptor substrate-1 (IRS-1), and the
uptake of glucose by adipocytes. The degradation of IRS-1
is one of the primary mechanisms that could cause insulin
resistance when exposed to pro-inflammatory cytokines
[27]. Notably, our data showed the increased serum con-
centrations of inflammatory markers in the ART group.
Furthermore, higher levels of inflammatory biomarkers
were observed in the MNT-IT than those in the MNT
group. Previous research also demonstrated the increased
levels of hs-CRP in GDM women who underwent IVF-ET
cycles [28].
Furthermore, recent evidence showed a correlation of
the elevated hs-CRP [29] and pro-inflammatory cyto-
kines [6, 7] with the development of GDM and insulin
resistance. More recently, IL-13, as an inflammatory
marker, was found to be associated with the conversion
of normoglycemia into type 2 diabetes mellitus and the
initiation of insulin therapy [30]. Hence, inflammatory
biomarkers may have indirectly affected insulin
requirement.
The current study demonstrates that assisted concep-
tion could be a prognostic factor for insulin requirement
in GDM populations. However, there were some limita-
tions in our study. We could not evaluate all aspects of
ART characteristics, and only a limited number of in-
flammatory biomarkers were evaluated. Another limita-
tion was the lower number of women requiring insulin
treatment. Moreover, the current research was per-
formed in Iranian GDM women. This may limit the
generalizability of the findings to other racial and ethnic
groups. It is necessary to study large populations with
other racial/ethnic groups in the future. Additionally, it
is possible that the underlying infertility, as opposed to
ART, could account for the study findings and the
present study was not capable of categorizing the effects
of assisted conception (ART) and nature of infertility;
hence, it is critical to consider this issue in future studies
on infertile patients who undergo non-IVF treatment as
a separate cohort.
In conclusion, our findings confirm that age ≥ 35 years
old, elevated levels of GTT-FBS and HbA1c are regarded
as the independent risk factors for insulin therapy in
GDM population. Furthermore, assisted conception
could be a predictive factor for insulin therapy in preg-
nancies complicated with GDM. However, this study is
the first report in this field, and more studies are war-
ranted to corroborate these results.
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